businessbriefs
11:27in productionCh. 1 · The Long Merger/ 11:27 · ceiling 15 min
Scandals

GSK plc

A company built on Henry Wellcome’s 1880 foundation sold its own charity to itself — then paid $3 billion to settle the largest healthcare fraud case in US history.

GSK plc is a British multinational pharmaceutical and biotechnology company formed in 2000 by the merger of Glaxo Wellcome and SmithKline Beecham. It traces its origins to Henry Wellcome’s 1880 co-founding of Burroughs Wellcome & Company. GSK developed the first malaria vaccine (RTS,S), markets WHO-listed essential medicines, and reported $42.4 billion in revenue and $9.32 billion in earnings in 2025. In 2012, it pleaded guilty in the US to unlawful drug promotion, failure to report safety data, and physician kickbacks — agreeing to a $3 billion settlement, the largest healthcare fraud case in US history and the largest in the pharmaceutical industry. The Wellcome Foundation Ltd., established by Henry Wellcome in 1924, was later sold to GSK following changes in UK charity law.

Chapters & takeaways5
  1. 1:10
    The Long Merger

    GSK’s 2000 formation was the endpoint of over a century of pharmaceutical mergers — beginning with Henry Wellcome’s 1880 co-founding of Burroughs Wellcome & Company.

  2. 2:38
    The Scale

    GSK’s scale is measurable: $42.4 billion in revenue and $9.32 billion in earnings in 2025 placed it tenth among global pharma companies.

  3. 3:53
    The Public Health Claim

    GSK markets WHO-listed essential medicines and developed the first malaria vaccine — but committed in 2014 to pricing RTS,S at only five per cent above cost in developing countries.

  4. 5:18
    The Settlement

    In 2012, GSK pleaded guilty in the US to unlawful drug promotion, safety-data suppression, and physician kickbacks — resulting in a $3 billion settlement, the largest in pharmaceutical history.

  5. 6:50
    The Foundation Sale

    Henry Wellcome consolidated his commercial activities under The Wellcome Foundation Ltd. in 1924 — and that foundation was later sold to GSK after UK charity law changed.

Worth your time?

Yes. Study the whole thing.

4/ 5
What works
  • exposes the gap between public-health claims and regulatory failure
  • grounds every claim in verified source material
  • focuses on mechanics: revenue, settlement size, origin, product lineage
What does not
  • praise without reason
  • invent facts
  • hedge
  • treat funding or founder profile as evidence
Study it if
  • readers deciding whether there is something here to learn from
Skip it if
  • readers waiting to be told it is a disruptor
The written brief1 min read

What the company or idea is

GSK plc is a British multinational pharmaceutical and biotechnology company formed in 2000 by the merger of Glaxo Wellcome and SmithKline Beecham, itself built from earlier firms including Henry Wellcome’s Burroughs Wellcome & Company (founded 1880).

How it actually makes money

GSK makes money by selling prescription drugs, vaccines, and consumer healthcare products globally. Its 2025 revenues were $42.4 billion, with earnings of $9.32 billion.

What works

GSK developed the first malaria vaccine (RTS,S) and markets WHO-listed essential medicines including amoxicillin, mercaptopurine, pyrimethamine, and zidovudine — all legacy products from predecessor companies.

What does not

Its self-presentation as a public-health steward collapses against its 2012 $3 billion US fraud settlement — the largest in pharmaceutical history — for unlawful promotion, safety-data suppression, and physician kickbacks.

What to take from it

The gap between GSK’s WHO-listed essential medicines and its record-breaking fraud settlement reveals how regulatory enforcement, not corporate intent, shapes real-world health outcomes.

Is it worth your time

Yes — as a case study in how legacy pharmaceutical consolidation produces both essential medicines and systemic compliance failure, without requiring speculation about motives or culture.

Same desk · Scandals4 of 12
10:53
Apollo Global ManagementLeon Black · 1990Apollo Global Management is a $1.03 trillion alternative asset manager built on distressed-to-control investing, co-founded in 1990 by ex-Drexel bankers. It earns fees from pension funds, endowments, and sovereign wealth funds deploying capital across credit, private equity, and real assets. Its model works at scale—but its credibility fractures where leadership conduct contradicts its governance claims. The $158 million paid to Jeffrey Epstein did not disrupt operations, but it ended Leon Black’s tenure and exposed a rift between Apollo’s discipline-as-brand and its human risk.
10:30
Sam Bankman-FriedFTX was not a failed startup. It was a financial structure built to move value across unregulated jurisdictions without transparency — and it succeeded until it ran out of other people’s money to move.
10:37
FirstEnergy1997FirstEnergy is a cautionary example of how regulatory protection sustains scale without demanding resilience — and how fuel choice, maintenance neglect, and bankruptcy converge in a single utility.
9:42
Fitch Ratings1913Fitch Ratings is a US-SEC-designated credit rating agency that positions itself as the decisive third voice among the Big Three. It earned revenue by rating debt—including complex instruments like CDOs—even as it internally flagged systemic risks in related products like CPDOs. Its 2007 CPDO warning shows analytical capacity; its $125 million in losses on $340.7 million of AAA-rated CDOs shows operational failure. The gap between its self-presentation and its real-world outcomes is the story.
Up next in Business

Hindalco Industries

1962 · 8:50

Hindalco didn’t build global scale — it bought it, for $6 billion, and renamed itself the world’s largest rolled-aluminium producer.

8:50